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Abstract World-wide, hepatitis C virus (HCV) accounts
for approximately 130 million chronic infections, with an
overall 3% prevalence. Four to 5 million persons are co-
infected with HIV. It is well established that HIV has a
negative impact on the natural history of HCV, including a
higher rate of viral persistence, increased viral load, and
more rapid progression to fibrosis, end-stage liver disease,
and death. Whether HCV has a negative impact on HIV
disease progression continues to be debated. However,
following the introduction of effective combination anti-
retroviral therapy, the survival of coinfected individuals has
significantly improved and HCV-associated diseases have
emerged as the most important co-morbidities. In this
review, we summarize the newest studies regarding the
pathogenesis of HIV/HCV coinfection, including effects of
coinfection on HIV disease progression, HCV-associated
liver disease, the immune system, kidney and cardiovascu-
lar disease, and neurologic status; and effectiveness of
current anti-HIV and HCV therapies and proposed new
treatment strategies.
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Introduction
Worldwide, there are an estimated 130 million chronic
hepatitis C virus (HCV) infections, with an overall prevalence
of 3%. Approximately 4 to 5 million persons are co-infected
withHIV.IntheUSandWesternEurope,amongHIV-infected
persons, HCV prevalence is 72% to 95% among injection
drug users (IDU), 1% to 12% in men who have sex with men
(MSM), and 9% to 27% in heterosexuals [1]. After acute
infection, 15% to 45% clear the virus, and 20% to 30% with
persistent viremia develop liver fibrosis, and potentially
cirrhosis, liver failure, and hepatocellular carcinoma [2].
Transmission is primarily through IDU or transfusion of
infected blood or blood products, although sexual transmis-
sion has been suggested among HIV-infected women and
documented among MSM [3–5].
HCV is an enveloped positive-strand RNA virus with six
genotypes. Genotype 1 predominates in North America [6]a n d
is associated with higher HCV RNA levels [7]. Replication
occurs primarily in hepatocytes but also in extrahepatic
reservoirs, including PBMCs, in patients with HIV [8].
Recent reviews have discussed many aspects of co-
infection, including new noninvasive methods for assessing
liver fibrosis [9, 10], current anti-HCV treatment regimens
[11–13], novel agents and therapeutic strategies [12, 14,
15￿], virologic and immunologic features in pathogenesis
[16–19], and clinical outcomes [16, 20, 21]. In this review,
we summarize other studies providing new information
regarding HIV/HCV coinfection.
Overview
The pathogenesis of HIV and HCV disease progression,
including immune system dysfunction and clinical compli-
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HIV Disease Progression in the Setting of HCV
Co-infection
Although most studies demonstrate increased mortality
among co-infected individuals, a recent meta-analysis of
over 30 studies with over 100,000 patients found no
increase in mortality in co-infected patients in the pre-
HAART era. Post-HAART, co-infection increased risk of
overall mortality but not of AIDS-defining conditions [22].
In contrast, an Italian cohort study found a twofold
increased AIDS risk among co-infected patients [23]. The
Women’s Interagency HIV Study (WIHS) found an almost
twofold increased AIDS risk among co-infected women
without a CD4 count <200 cells/μL and for ART-naïve
women [24￿￿]. The Italian cohort showed increases in
bacterial and mycotic infections and WIHS found increases
in bacterial pneumonia, HIV encephalopathy, and wasting
syndrome, suggesting the need for earlier and more
aggressive HIV and HCV treatment in co-infected individ-
uals [23, 24￿￿].
Recent studies found high levels of T-cell activation in
co-infected compared to HIV monoinfected individuals
even following HAART [24￿￿, 25, 26]. Chronic immune
activation may lead to immune dysfunction and cytokine
production, causing enhanced HIV and HCV replication
and lower T-cell counts [25]. The WIHS study showed that
high levels of activated CD8 T cells are associated with
incident AIDS among HCV-viremic women but not HCV-
uninfected women, and CD4 activation predicted AIDS in
both groups [24￿￿, 25]. Suppression of HCV with therapy
reduces activation [26]. These results again support early
treatment of HIV and HCV.
Several pathways for active HCV infection impacting
HIV infection have been proposed (Table 1). HCV co-
infection may increase immune activation, leading to CD4
T-cell apoptosis in HIV-untreated patients and more rapid
Fig. 1 Pathogenesis of HIV/HCV co-infection: Immune activation and dysregulation, effects on HIV and HCV disease progression, and
complications in multiple organ systems
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impact of HCV infection on CD4 cell recovery following
HAART is conflicting; some reports note a poorer CD4
response in co-infected compared to monoinfected patients
[28], and others do not [27, 29–31].
HCV-Associated Liver Disease Progression
in the Setting of HIV Co-infection
Despite reductions of morbidity and mortality in HIV-
infected individuals on HAART, liver-related deaths now
Table 1 Pathogenesis of HIV/HCV-associated diseases and complications
Affected organ/
system
Complication Proposed mechanism of action References
Immune ↑ HIV disease
progression
↑ CD4 and CD8 T-cell activation, leading to ↑ immune dysfunction
and cytokine production, enhanced HIV and HCV production,
and ↓ T-cell counts
[24￿￿, 25, 26]
HCV-induced ↑ CD4 T-cell apoptosis, leading to severe
immunodeficiency
[27]
HCV-induced ↓ CD4 recovery post-HAART [28]
↑Cryoglobulinemia ↑ Cryoglobulin production by activated B cells [53]
↓ CRP production
in liver
Unknown [54]
Liver ↑ Steatosis HIV-related mitochondrial translocation (↑LPS)-induced
immune activation
[16, 18, 26, 42]
↑ Fibrosis ↑ Activation of CD4 and CD8 T cells [26]
↑ Cirrhosis ↑ Levels of cytokines (eg, IL-4, IL-5, IL-13, TGF-β, IFN-γ
and TNF-α ) and chemokines (eg, IP-10 and IL-8)
[17, 18]
↑ ESLD HIV-induced ↓ HCV-specific CD4 and CD8 T-cell responses [16, 17]
↑ HCC ↑ Levels of cytotoxic CD8 T cells in liver [39, 40]
↑ Activation of HSC [18, 19, 43]
↑ Apoptosis of hepatocytes and HSC, mediated by TRAIL [16–19, 44]
↑ Collagen synthesis by HIV-infected HSC [43]
↑ HSC production of collagen by HIV-infected Kupffer cells [16]
Insulin resistance–associated hyperinsulinemia and
hyperglycemia stimulate HSC to ↑ connective tissue
growth factor and extracellular matrix
[45, 46]
Liver/metabolic Diabetes mellitus Unknown [68]
Insulin resistance Unknown [46]
Cardiovascular HIV- and HCV-associated chronic inflammation leads to
endothelial dysfunction, causing ↑ sCAMS
[59, 60]
Hematologic Thrombocytopenia Sequestration of platelets in cirrhosis and portal hypertension [55]
↓ Production of thrombopoietin in advanced liver disease [55]
Kidney Proteinuria Unknown [56]
Acute interstitial nephritis Unknown [58]
Acute tubular necrosis
MPGN Stimulation of B cells to ↑cryoglobulin production and
deposits in renal vessels
[53, 56–58]
Acute renal failure
Chronic kidney disease
Gastrointestinal Mitochondrial
translocation
HIV-inducted ↑gut permeability and depletion of CD4 cells
from gut-associated lymphoid tissue
[16]
Central/peripheral
nervous
Neurocognitive
syndromes
HIV and HCV replication in brain [61]
Peripheral neuropathy
syndromes
HCV core protein activates glia and ↑HIV-associated
neurotoxicity
[62]
LPS-induced monocyte activation and ↑HIV-associated
dementia
[65]
Bone Osteoporosis ↓ Bone mass in chronic liver disease [70]
Osteonecrosis
CRP C-reactive protein; ESLD end-stage liver disease; HCC hepatocellular carcinoma; HSC hepatic stellate cells; LEE liver enzyme elevations;
LPS lipopolysaccharides; MPGN membranoproliferative glomerulonephritis; sCAMS, soluble cellular adhesion molecules; TRAIL, tumor necrosis
factor–related apoptosis-inducing ligand
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primarily due to HCV co-infection. HCV-associated liver
disease, including fibrosis, cirrhosis, and end-stage liver
disease (ESLD), is accelerated in HIV-infected individuals.
Progression to cirrhosis is threefold higher in co-infected
than monoinfected patients, and approximately 33% prog-
ress to cirrhosis in less than 20 years [32￿￿]. A recent meta-
analysis of 17 studies found cirrhosis in 21% of 3567 co-
infected individuals after 20 years of infection and 49%
after 30 years [33]. Another meta-analysis of 27 studies
among 7666 individuals found that co-infected individuals
had a twofold increased rate of cirrhosis compared to
monoinfected [33]. Severe liver fibrosis and cirrhosis were
also found in 10% to 25% of co-infected HCV viremic
patients with normal alanine aminotransferase (ALT) levels
[34, 35]. A 20-year prospective study found increased risk
of hepatitis/liver-related deaths despite HAART among co-
infected drug users (DUs) compared to HCV-monoinfected
DUs, providing further support that HIV accelerates liver
disease in the HAART era [36].
Hepatic steatosis (HS), a common (40%–75%) compli-
cation of HCV monoinfection and HCV/HIV co-infection,
is associated with rapid fibrosis progression [37], although
a recent meta-analysis found that it is not necessarily more
common in co-infected than HCV monoinfected patients
[38]. HS is associated with increased body mass index,
diabetes, elevated ALT levels, HCV genotype 3, necroin-
flammation, and fibrosis [37, 38].
Pathogenesis of Liver Disease in Co-infection
Mechanisms to explain accelerated liver disease in co-
infected patients are not well understood but may include
direct viral effects and immunologic alterations such as
immune activation, apoptosis, and diminished HCV-
specific T-cell responses (Table 1)[ 16–18]. Immune
activation by HIV induces cytokine changes (eg, IL-4, IL-
5, and IL-13, TGF-β) that increase liver inflammation and
fibrosis [17, 18]. Coinfection increases apoptosis of
hepatocytes through a Fas/FasL pathway that could account
for accelerated liver disease [17, 18]. Accumulation of
cytotoxic CD8 T cells in the liver that increases inflamma-
tory mediators in co-infected compared to HCV-
monoinfected patients may also lead to increased tissue
damage in co-infected patients [39, 40]. New evidence
shows HIV-specific CD8 T cells accumulate in the liver in
co-infection and produce TNF-α, which is associated with
liver fibrosis [18, 41]. Recently, HIV-related microbial
translocation that causes systemic activation has been
linked with severity of HCV-related liver disease [42].
Increasing evidence finds HIV replication in hepatocytes
and hepatic stellate cells (HSC) [18, 19, 43]. HIV infection of
activated HSC promotes collagen expression and secretion of
proinflammatory cytokines [43]. In addition to infection, HIV
proteins induce hepatocytes to apoptosis and release of
inflammatory chemokines and cytokines that promote fibrosis
[18, 19]. Further, HIV and HCV co-infection may increase
tumor necrosis factor–related apoptosis—inducing ligand
(TRAIL)-mediated apoptosis of hepatocytes [17, 18, 44].
Insulin resistance (IR), also common in chronic HCV,
appears to be critical in liver steatosis and liver disease
progression. A recent study found IR associated with liver
fibrosisandsteatosisinHCV-monoinfectedbutnotco-infected
patients [45], but another study found IR associated with liver
fibrosis in co-infected patients [46]. The mechanism for IR in
liver disease among HCV-infected patients is unknown, but
hyperinsulinemia and hyperglycemia stimulate HSC, leading
to increased connective tissue growth factor and accumula-
tion of extracellular matrix [46].
New Technologies for Diagnosis and Staging of Liver
Disease
Although liver biopsy is the gold standard for staging liver
disease, its invasive nature, serious complications, sampling
error, and inherent heterogeneity have prompted research to
identify noninvasive methods [10, 21, 47]. Promising
methodologies include transient elastography/elastometry
(TE) and serologic biomarkers.
TE, which uses ultrasound readings to measure liver
elasticity or stiffness, is well tolerated and can accurately
stage fibrosis and cirrhosis [35, 47], although discriminat-
ing power may be low [48]. TE may also be useful in
patients with normal aminotransferase levels [34, 35].
Serological markers correlated with liver fibrosis stage can
be classified into three groups: 1) indices from routine blood
tests of liver function [eg, APRI (aspartate aminotransferase
[AST]-to-platelet ratio index) and Fib-4 (age, AST, platelets,
and ALT level)]; 2) markers of extracellular matrix metabo-
lism (eg, hyaluronic acid); and 3) indices combining markers
of both types [49]. These are valid markers of liver fibrosis
and predictive of HCV-related liver mortality in monoin-
fected and co-infected individuals [49, 50].
Other promising noninvasive technologies include DNA
microarray analysis to identify novel biomarkers to assess
fibrosis [51] and MRI to measure steatosis and predict
adipose tissue and metabolic factors associated with
steatosis in co-infected patients [52].
Other Complications of HIV/HCV Co-infection
Other Immune Dysregulation and Hematologic Disorders
Although both HCV and HIV activate B cells, their
interaction in the lymphoid system needs study [16]. Both
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lins, but a recent study found only a marginal influence
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infected patients [53]. A large retrospective study found
HCV co-infected patients had lower C-reactive protein
(CRP) levels than HIV monoinfected patients, suggesting
that HCV decreases the liver’s ability to secrete CRP [54].
HIV-associated thrombocytopenia remains an important
problem in the HAARTera and is associated with cirrhosis
but also HCV infection without serious liver disease [55].
This may be an important consideration in staging liver
disease using APRI, which is calculated using platelet
count.
Kidney Disease
A meta-analysis of 24 observational studies and clinical
trials found that HCV co-infection is associated with
increased HIV-related kidney disease risk, including
proteinuria and acute renal failure, compared to HIV
monoinfection [56]. A large retrospective study of HIV-
infected veterans also found that HCV co-infection was
associated with higher chronic kidney disease rates; HCV
prevalence increased with worsening estimated glomeru-
lar filtration rate (eGFR) [57]. The largest study of
biopsy-proven renal disease found that HIV/HCV-associ-
ated nephropathies reduced survival compared to HCV
monoinfection [58].
Cardiovascular Disease
HCV co-infection is associated with a higher prevalence
of cardiovascular disease (CVD) than HIV monoinfec-
tion. HCV co-infection is associated with increased risk
of cerebrovascular disease and a trend toward increased
risk of acute myocardial infarction among HIV-infected
patients [59]. HIV-infected patients have an increased
CVD risk because HAART and HIV-associated chronic
inflammation can cause endothelial dysfunction [60].
Circulating soluble cellular adhesion molecules (CAMS)
released by the vascular endothelium, including soluble
intercellular adhesion molecule-1 (sICAM-1) and vascular
adhesion molecule-1 (sVCAM-1), are higher in co-
infected patients stably treated with HAART than healthy
controls [60]. HAART can lower sICAM-1 and sVCAM-
1, suggesting that HAART can improve endothelial cell
function and decrease CVD risk by decreasing plasma
HIV-RNA levels, increasing T-cell number and function,
and decreasing immune activation. Patients with advanced
HCV infection have higher levels of sICAM-1 and
sVCAM-1, suggesting that HCV infection also causes
endothelial dysfunction, and response to HCV treatment
might reduce CVD risk [60].
Neurologic Status
Both HIVand HCV replicate in the brain and cerebrospinal
fluid (CSF) and are implicated in neurocognitive and
peripheral neuropathy syndromes [61–64]. Co-infected
subjects show significant cognitive-motor impairment com-
pared to HIV-monoinfected patients [63] and higher rates of
global cognitive impairment, especially in learning and
memory [64]. Recently, HCV RNA and antigens were
found in brains of co-infected patients [61]. HCV core
protein activates human glia and contributes to HIV-
associated neurotoxicity [62]. Plasma lipopolysaccharides
(LPS), indicators of microbial translocation from the gut,
induce monocyte activation in HIV infection and may
contribute to HIV-associated dementia (HAD) by increased
trafficking of activated monocytes into the brain [65]. That
LPS levels are higher in HCV co-infected patients suggests
that HCV may influence HAD pathogenesis [65].
In contrast to findings of increased neurocognitive impair-
ment in co-infected patients, a retrospective study from the
AIDSClinicalTrialsGroupLongitudinalLinkedRandomized
Trials (ALLRT) found that active HCV infection did not
exacerbate clinically significant neurocognitive dysfunction
or peripheral neuropathy in individuals with controlled HIV
infection [66].
Because sensory neuropathy (SN) is a common compli-
cation of HIV infection and certain HIV treatments and is
associated with HCV infection, there are concerns about
possible synergistic effects of these viruses on the periph-
eral nervous system [67]. However, a survey among HIV-
infected patients in six international sites found HCV
seropositivity was not associated with increased SN risk
[67].
Diabetes Mellitus
One of the largest prospective studies of HIV-infected
persons and uninfected controls found that while HIV
infection itself is not associated with increased diabetes
mellitus (DM) risk, HCV coinfection is associated with
higher risk, with a similar trend in the HIV-uninfected
group. Risk was not altered by presence of liver damage as
measured by ALT and AST levels [68]. A large prospective
study of HIV-infected and uninfected women also found
that HCV infection and higher HCV RNA levels were
associated with incident diabetes, suggesting that HCV-
infected patients should be screened to diabetes [69].
Bone Complications
Among the emerging comorbidities in the HAART era are
bone complications, including osteonecrosis or osteoporo-
sis, but the role of HCV and HAART is controversial [70].
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10-year incidence of bone fractures was 3.6-fold higher in
HCV co-infected patients perhaps because patients with
chronic liver disease have decreased bone mass [70]. Active
monitoring of co-infected patients is recommended for
prevention of bone fractures.
Treatment of HIV in Co-infected Patients
The timing of initiation of HAART in relation to anti-HCV
therapy in co-infected patients poses challenges for clini-
cians. HAART may slow liver disease progression and
might therefore be initiated earlier in co-infected than HIV
monoinfected patients [11, 71]. On the other hand, HAART
might increase fibrosis in co-infected patients through
cumulative hepatotoxicity [11, 13, 72]. Recent guidelines
recommend that HAART generally be initiated first to slow
liver disease progression and increase CD4 count, but
certain drugs should be avoided (eg, ZDV, didanosine,
stavudine, and abacavir) and others should be monitored for
hepatoxicity [32￿￿, 73￿￿]. Although ART interruption is
deleterious to the HIV-infected population, the first ran-
domized study of ART interruptions in HCV co-infected
persons found that interruption was particularly unsafe in
co-infected persons because of elevated nonopportunistic
disease death, though not liver disease death [74].
Treatment of HCV in Co-infected Patients
Treatment of chronic HCV in co-infected individuals is a
priority because of their more rapid progression to ESLD,
poor tolerance of ART, and greater risk of hepatoxicity
[75]. Clearance is associated with regression of liver
fibrosis and reduced risk of ART hepatoxicity [75, 76].
However, anti-HCV treatment is less effective in co-
infected patients [75].
HCV treatment guidelines for co-infected patients are
published [77], but there is a lack of consensus regarding
key factors that might inform initiation and duration of
therapy, including stage of HIV and HCV disease and viral
load, HCV genotype, degree of hepatic fibrosis, and
patient’s readiness to tolerate and adhere to treatment.
These have clinical importance because they influence
safety, tolerability, and success of therapy. Investigations
continue to identify better predictors of treatment
response that could guide the pretreatment evaluation
process and permit earlier termination of ineffective
treatment, reducing additional cost and adverse effects
of ineffective therapy. There are no guidelines for the
clinical management and treatment of co-infected chil-
dren, and the limited experience in their management and
lack of evidence base to guide policy is a barrier to
achieving optimal care [78].
Current Standard Therapeutic Regimen
Pegylated interferon plus ribavirin (pegIFN + RBV) is the
standard HCV treatment in both monoinfected and co-
infected patients [77, 79]. Although guidelines recommend
a fixed course of 48 weeks to optimize HCV treatment in
co-infected patients [77], a recent study explored response-
guided therapy, with duration based on virologic response
at treatment weeks 4, 12, and 24 [80]. The results were
encouraging, with 55% achieving a sustained viral response
(SVR). Among patients who failed a prior suboptimal
treatment regimen, retreatment with pegIFN + RBV for
12 months achieved an SVR in nearly one third, an
encouraging outcome in light of earlier studies with lower
retreatment response rates [75].
Predictors of Treatment Response
The best predictors of treatment outcome are virologic
response kinetics, including rapid viral response (RVR),
defined as HCV viral load below the level of detectability
4 weeks after treatment initiation, early viral response
(EVR), defined as undetectable HCV load or a 2 log drop
from baseline 12 weeks after therapy initiation, and SVR,
defined as undetectable HCV load 24 weeks after therapy
completion [81]. While undetectable HCV RNA at week 4
is the best predictor of SVR in co-infected patients,
baseline serum HCV RNA is an independent predictor of
SVR in HCV genotype 1 patients [82]. Although these
predictors use absence of serum HCV RNA as the marker
of treatment success, negative-strand HCV RNA in
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Results of investigations of impact of baseline CD4
count on viral response kinetics are mixed. In a large
randomized study of pegIFN + RBV in co-infected patients
that included a small number of patients with CD4 counts
<200 cells/μL, SVR rates tended to increase with higher
CD4 counts in genotype 1, but were independent of
baseline CD4 counts for genotypes 2/3 [83]. Another large
randomized study of co-infected patients found the efficacy
of pegIFN + RBV was not different in patients with and
without severe immunodeficiency, suggesting that ad-
vanced immunosuppression is not a major factor in
predicting SVR [84].
In the AIDS Clinical Trials Group (ACTG), HCV
quasispecies complexity was an important predictor of
treatment outcomes, with lower baseline complexity asso-
ciated with EVR and a decrease in complexity by 4 weeks
associated with RVR [81]. Extrahepatic replication in B,
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treatment has predicted viral relapse and, although the
assays are cumbersome, they might identify patients whose
treatment should be extended to 72 weeks [85].
Adverse Events Associated with Anti-HCV Therapy
IFN-related adverse events (AEs), specifically CD4 cell
declines and psychiatric effects, are reported to be more
common in co-infected virologic responders than non-
responders [86]. Also with successful IFN therapy, alter-
ations in cytokine pools necessary to improve immune
function may have negative effects in the brain by
traversing the blood–brain barrier [86].
The first meta-analysis of sex difference in AEs in
co-infected individuals showed that women were more
likely to develop AEs requiring treatment discontinua-
tion or dose modification and to develop them earlier,
but the types of AEs were similar [87]. Women on
NNRTIs were more likely to discontinue therapy, and
women on AZT were more likely to experience AEs,
suggesting that in women antiviral regimen is an
important predictor of treatment discontinuation and
modification.
HAART as HCV Therapeutic Agent
Table 2 summarizes the therapeutic and adverse effects of
HAART on HCV disease, alone or in combination with
pegIFN + RBV. Early HAART may protect co-infected
patients from liver fibrosis progression [71]. HAART can
significantly decrease liver HCV necroinflammatory activ-
ity in co-infected patients with relatively preserved immune
status, possibly by inhibiting HIV replication in the liver or
decreasing level of proinflammatory cytokines [71]. In
vitro, the HIV protease inhibitor nelfinavir inhibits HCV
replication at concentrations showing no cytotoxicity and
acts synergistically with IFN against HCV, suggesting that
nelfinavir could improve the antiviral effects of IFN in co-
infected patients [88].
Some ART medications, especially abacavir, may com-
promise the response to anti-HCV therapies, perhaps by
competing intracellularly with RBV [89]. However, a large
cohort study did not find an association of abacavir or other
ARTs with reduced EVR or SVR [90].
The combination of HAARTand pegIFN + RBN may also
increase the frequency of AEs [13]. HCV therapy with
zidovudine (ZDV) has been associated with higher anemia
rates [13]. RBV with NRTIs such a didanosine has been
Table 2 Therapeutic and adverse effects on HCV disease of antiretroviral agents alone and in combination with anti-HCV therapy in co-infected
individuals
Therapy Therapeutic effect Reference Adverse event Reference
HAART ↓ HIV replication in liver [71] ↑ Liver enzymes (LEE) at HAART
initiation (IRD)
[93]
↓ Proinflammatory cytokines [39, 71] ↑ Hepatoxicity [13, 72]
↓ Hepatic necroinflammatory activity [71]
↓ Liver necrosis and inflammation [11]
↓ Liver disease progression [11, 71] ↑ Hepatocellular necrosis
and steatosis
[13]
↓ Liver mortality [13]
Protease inhibitors ↓ HCV replication in vitro [88]
↓ Hepatotoxicity after SVR [76]
NRTI ↑ Steatosis [11]
↑ Hepatotoxicity after SVR [76]
Efavirenz ↓ Hepatotoxicity after SVR to IFN [76]
HAART + PegIFN + RBV
ZDV + PegIFN + RBV ↑ Anemia [13, 32￿￿]
PI + pegIFN + RBV ↓ Hepatotoxicity [76]
Synergistic ↓ HCV replication
in vitro
[88]
NNRTI + pegIFN + RBV ↓ Hepatotoxicity [76]
NRTI + pegIFN + RBV ↑ Mitochondrial toxicity [13, 32￿￿, 91, 92]
↑ Steatosis and fibrosis [91, 92]
↓ Response to anti-HCV therapies [32￿￿, 89]
HAART highly active antiretroviral therapy; IFN interferon; IRD immune restoration disease; NNRTI nonnucleoside reverse transcriptase inhibitor
(efavirenz); NRTI nucleoside reverse transcriptase inhibitor (abacavir, didanosine, stavudine); PegIFN + RBV pegylated interferon + ribavirin; PI
protease inhibitor (nelfinavir); RBV ribavirin; SVR sustained viral response to pegIFN + RBV; ZDV zidovudine
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and worsening steatosis/fibrosis [13, 91, 92]. MT-associated
laboratory abnormalities are frequent during pegIFN + RBV
therapy in combination with HAART, especially when high
RBV doses are used [91]. However, patients with signs of
MT show faster decreases in HCV RNA levels and achieve
higher SVR rates, probably because MT reflects increased
intracellular RBV levels. Clinicians should be aware of
potential interactions between NRTIs and RBV in co-
infected patients, and increased lactate levels might be useful
to adjust RBV dosage to optimal efficacy [91].
Co-infected patients may experience liver enzyme
elevation (LEE) following HAART initiation [93]. CD4 T-
cell increases early after HAART initiation were higher
among co-infected patients who developed LEE than co-
infected or monoinfected patients who did not develop
LEE, suggesting that LEE early in HAART is a form of
immune restoration disease (IRD) or immune reconstitution
inflammatory syndrome (IRIS) involving an immune
reconstitution-induced inflammatory response to HCV-
specific antigens [94]. The risk of LEE after HAART
initiation is lower in co-infected patients with SVR to anti-
HCV therapy, arguing for HCV treatment before commenc-
ing HAART [76]. In contrast, an Italian multicenter study
found that HAART is not a risk factor for LEE in co-
infected patients and does not modify the association
between coinfection and the risk of LEE [95].
Novel New Therapies
Because pegIFN + RBV leads to successful outcome in only
40% to 50% of monoinfected and 30% of co-infected patients,
more effective drugs are being developed [14, 15￿]. As in HIV,
triple-combination therapies may be more effective in
achieving virologic cure and less prone to resistance
development in monoinfected and co-infected patients. NS3
protease and NS5B polymerase enzymes, essential for HCV
replication, are primary targets. Results for inhibitors targeting
these enzymes (combined with pegIFN + RBV) are positive
in clinical trials [11, 96, 97] and preclinical studies [98–100].
T h em o s tp r o m i s i n go ft h e s ea r et h ep r o t e a s ei n h i b i t o r s
telaprevir and boceprevir, which are expected to be approved
this year [101, 102]. Taribavirin, an oral RBV prodrug with
significantly lower anemia rates, is in phase III trials [103].
Anti-HCV Treatment in Acute HCV Infection
Increasing acute HCVinfections among HIV-infected popula-
tions were reported in Europe in the early 2000s, most due to
sexual transmission [4]. Because HIV-infected persons have
delayed HCV antibody production, screening with third-
generation ELISA tests in the first 6 months is inadequate
[104]. A recent study found the median time from HCV
infection to antibody production was 158 days but the median
ALT at the first positive PCR was 65 IU/mL, suggesting that
elevated ALTs in at-risk patients should indicate HCV testing
by PCR to diagnose and treat infection early [104].
Treatment data for acute HCV infection in co-infected
patients have emerged only recently, and questions remain
regarding optimal time, indication, therapy duration, and
whether parallel initiation of HAART is necessary [13]. The
Australian Trial in Acute Hepatitis C (ATAHC) found high
treatment success after 24 weeks of therapy for both acute
and early chronic HCV infections in co-infected patients,
with an SVR of 80% [105]. RVR had a 100% positive
predictive value, suggesting that RVR is an important
predictor of SVR in acute and chronic HCV infection.
Results for three patients suggest that an SVR is possible
even during primary HIV infection [106].
Conclusions
HIV-infected patients should be screened regularly for HCV
co-infection, particularly if they are in high-risk groups.
Sexual transmission of HCV needs to be included in patient
counseling both for HIV-infected men and women. Increased
progression rates to AIDS and liver disease in co-infected
individuals may require earlier and more aggressive treatment
of both infections. However, following treatment initiation,
patients should be monitored for AEs, with prompt interven-
tion to support continued treatment. For most co-infected
patients,HAARTshould beinitiated beforeanti-HCV therapy
to slow liver progression and increase CD4 counts. Promising
newtherapiesavailable inthe nearfuturewill increaseSVRin
co-infected individuals.
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